Despite a push toward comparative effectiveness research, Estellat and Ravaud1 present evidence that the majority of randomized controlled trials of biologic DMARDs continue to compare new agents with placebos rather than approved active medications. Their data are derived from study protocols listed at ClinicalTrials.gov. The authors found that, among randomized controlled trials completed since 2002 or still ongoing, only 5 (5%) of 91 trials involved a head-to-head comparison of DMARDs. The authors draw particular attention to 63 of these trials involving patients with a potentially high level of active disease who had never been treated with any type of DMARD before. Among these trials, 54 (86%) were designed so that control patients received their current “ineffective” treatment alone or with a placebo added. The authors conclude that most current studies of biologic DMARDs expose patients in control arms to long periods of care with placebos, placing them at risk for deterioration of their condition while producing scientific results of questionable usefulness.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 4
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.